According to UNAIDS, in 2007 globally there were 33.2 million people livingwith HIV (a 14% increase from 2001), 2.5 million people were newly infectedwith the virus, and 2.1 million people died of AIDS-related illnesses.Large percentages of those infected, estimated to be 30% of the over 1million living with the virus in the U.S. and much higher in other regions,are unaware of their HIV-positive status. Testing is the key toindividuals becoming aware of their HIV status. The World AIDS Day 2008 OneMillion Tests Campaign calls for a grass roots approach for current testingprograms around the world to increase their efforts by adapting pre-testcounseling sessions to group sessions, setting testing goals, resourcingnew rapid test kits, breaking out of the clinic and putting up a tent inthe community to provide fast and easy testing.

Every year since 1997, the world unites on December 1 to commemorate WorldAIDS Day. The World AIDS Day Campaign has chosen "Leadership" as the themefor World AIDS Day 2007 and 2008. This theme will continue to be promotedwith the slogan "Stop AIDS. Keep the Promise." and will build on the 2006World AIDS Day focus on accountability. The primary objective of the WorldAIDS Day Campaign for the next 5 years is that leaders and decision makersdeliver on promises regarding AIDS, including the provision of universalaccess to treatment, care and support and prevention services.

"We are proud to support AIDS Healthcare Foundation and the World AIDS Day2008 One Million Tests Campaign by providing access to rapid HIV testing.Being tested and knowing one's HIV status is the critical first step inobtaining treatment and preventing further transmission of disease," saidLawrence Siebert, Chembio's President and CEO.

"On behalf of AHF and all the clients we serve around the world, I want toexpress our profound thanks to Mr. Siebert and Chembio Diagnostics for thislifesaving contribution to our ambitious global 'One Million Tests'campaign," said Michael Weinstein, President of AIDS Healthcare Foundation,the largest AIDS organization in the US. which currently provides medicalcare and services to more than 85,000 individuals in 22 countries worldwidein Africa, Latin America/Caribbean, Asia as well as in the US. "HIV testinghas become one of the single most important elements in today's globalfight against HIV and AIDS. People the world over have been found to modifytheir behavior to protect their partners once they know their HIV status.The use of reliable, easy-to-use test kits such as Chembio's HIV 1/2STAT-PAK allows us to link those individuals found to be HIV-positive toappropriate medical care and antiretroviral treatment as well as help breakthe chain of new infections. This contribution of test kits from Chembiowill undoubtedly go a long way in helping us achieve our overall World AIDSDay global testing goals."

ABOUT CHEMBIO DIAGNOSTICS

Chembio Diagnostics, Inc. develops, manufactures, licenses and marketsproprietary rapid diagnostic tests in the growing $5 billion point-of-caretesting market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIVtests are marketed in the U.S. by a third party company. Chembio marketsits HIV STAT-PAK® line of rapid HIV tests internationally to governmentand donor-funded programs directly and through distributors. Chembio alsohas rapid tests for veterinary tuberculosis and chagas disease. In 2007Chembio received a U.S. patent for its Dual Path Platform (DPP®)technology which has significant advantages over lateral-flow technologies.This technology is providing Chembio with a significant pipeline ofbusiness opportunities for the development and manufacture of new productsbased on DPP®. Headquartered in Medford, NY, with approximately 100employees, Chembio is licensed by the U.S. Food and Drug Administration(FDA) as well as the U. S. Department of Agriculture (USDA), and iscertified for the global market under the International StandardsOrganization (ISO) directive 13.485.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may beforward-looking statements within the meaning of the Securities Act of1933, as amended. Forward-looking statements include statements regardingthe intent, belief or current expectations of the Company and itsmanagement. Such statements are estimates only, as the Company has notcompleted the preparation of its financial statements for those periods,nor has its auditor completed the audit of those results. Actual revenuemay differ materially from those anticipated in this press release. Suchstatements reflect management's current views, are based on certainassumptions and involve risks and uncertainties. Actual results, events,or performance may differ materially from the above forward-lookingstatements due to a number of important factors, and will be dependent upona variety of factors, including, but not limited to Chembio's ability toobtain additional financing, to obtain regulatory approvals in a timelymanner and the demand for Chembio's products. Chembio undertakes noobligation to publicly update these forward-looking statements to reflectevents or circumstances that occur after the date hereof or to reflect anychange in Chembio's expectations with regard to these forward-lookingstatements or the occurrence of unanticipated events. Factors that mayimpact Chembio's success are more fully disclosed in Chembio's most recentpublic filings with the U.S. Securities and Exchange Commission.

Contacts:Susan NorcottChembio Diagnostics, Inc.631-924-1135 x125snorcott@chembio.com